[go: up one dir, main page]

CO2019009000A2 - Combinaciones farmacéuticas para tratar cáncer - Google Patents

Combinaciones farmacéuticas para tratar cáncer

Info

Publication number
CO2019009000A2
CO2019009000A2 CONC2019/0009000A CO2019009000A CO2019009000A2 CO 2019009000 A2 CO2019009000 A2 CO 2019009000A2 CO 2019009000 A CO2019009000 A CO 2019009000A CO 2019009000 A2 CO2019009000 A2 CO 2019009000A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical combinations
tyr
treat cancer
dpro
cys
Prior art date
Application number
CONC2019/0009000A
Other languages
English (en)
Inventor
Michael Bauer
Leon Hooftman
Barbara Romagnoli
Original Assignee
Polyphor Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyphor Ag filed Critical Polyphor Ag
Publication of CO2019009000A2 publication Critical patent/CO2019009000A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a combinaciones farmacéuticas que comprenden un compuesto de fórmula I o una sal farmacéuticamente aceptable del mismo y ciclo (-Tyr-His-Ala-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro-) que tiene un enlace de disulfuro entre Cys4 y Cys11 o una sal farmacéuticamente aceptable del mismo y su uso en un método para la prevención, retraso o progreso de tratamiento de cáncer en un sujeto.
CONC2019/0009000A 2017-02-20 2019-08-20 Combinaciones farmacéuticas para tratar cáncer CO2019009000A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17020059 2017-02-20
PCT/EP2018/025042 WO2018149552A1 (en) 2017-02-20 2018-02-20 Pharmaceutical combinations for treating cancer

Publications (1)

Publication Number Publication Date
CO2019009000A2 true CO2019009000A2 (es) 2020-01-17

Family

ID=58108397

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0009000A CO2019009000A2 (es) 2017-02-20 2019-08-20 Combinaciones farmacéuticas para tratar cáncer

Country Status (19)

Country Link
US (2) US20210187059A1 (es)
EP (1) EP3582804A1 (es)
JP (1) JP2020508315A (es)
KR (1) KR20190138633A (es)
CN (1) CN110603051A (es)
AU (1) AU2018221371A1 (es)
BR (1) BR112019017047A2 (es)
CA (1) CA3053857A1 (es)
CL (1) CL2019002325A1 (es)
CO (1) CO2019009000A2 (es)
EA (1) EA201991688A1 (es)
IL (1) IL268416B2 (es)
MA (1) MA47502A (es)
MX (1) MX2019009779A (es)
PE (1) PE20200149A1 (es)
PH (1) PH12019550138A1 (es)
SG (1) SG11201907217RA (es)
UA (1) UA126029C2 (es)
WO (1) WO2018149552A1 (es)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11725015B2 (en) 2017-04-05 2023-08-15 President And Fellows Of Harvard College Macrocyclic compound and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022167157A1 (en) * 2021-02-05 2022-08-11 Spexis Ag Eribulin-balixafortide combinations for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140163095A1 (en) * 2012-12-04 2014-06-12 Eisai R&D Management Co., Ltd. Use of eribulin in the treatment of breast cancer
RU2699545C2 (ru) * 2014-05-28 2019-09-06 ЭЙСАЙ Ар ЭНД Ди МЕНЕДЖМЕНТ КО., ЛТД Применение эрибулина в лечении рака

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11725015B2 (en) 2017-04-05 2023-08-15 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US12421248B2 (en) 2017-04-05 2025-09-23 President And Fellows Of Harvard College Macrocyclic compound and uses thereof
US11498892B2 (en) 2017-07-06 2022-11-15 President And Fellows Of Harvard College Fe/Cu-mediated ketone synthesis
US11548898B2 (en) 2017-07-06 2023-01-10 President And Fellows Of Harvard College Synthesis of halichondrins
US11407762B2 (en) 2017-11-15 2022-08-09 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof
US11814398B2 (en) 2017-11-15 2023-11-14 President And Fellows Of Harvard College Macrocyclic compounds and uses thereof

Also Published As

Publication number Publication date
AU2018221371A1 (en) 2019-08-22
EP3582804A1 (en) 2019-12-25
US20210187059A1 (en) 2021-06-24
CN110603051A (zh) 2019-12-20
US20230381270A1 (en) 2023-11-30
MX2019009779A (es) 2019-12-19
BR112019017047A2 (pt) 2020-04-28
IL268416A (en) 2019-09-26
JP2020508315A (ja) 2020-03-19
PE20200149A1 (es) 2020-01-17
PH12019550138A1 (en) 2020-03-16
SG11201907217RA (en) 2019-09-27
MA47502A (fr) 2019-12-25
EA201991688A1 (ru) 2020-02-12
UA126029C2 (uk) 2022-08-03
CL2019002325A1 (es) 2020-05-15
WO2018149552A1 (en) 2018-08-23
CA3053857A1 (en) 2018-08-23
IL268416B2 (en) 2023-05-01
IL268416B1 (en) 2023-01-01
KR20190138633A (ko) 2019-12-13

Similar Documents

Publication Publication Date Title
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CO2019009000A2 (es) Combinaciones farmacéuticas para tratar cáncer
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
MX2017010982A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
AR101740A1 (es) Terapia de combinación y composiciones
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CL2018002807A1 (es) Métodos de tratamiento de cánceres pediátricos.
DOP2017000111A (es) Inhibidor de cinasa aurora a
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
TW201613578A (en) Pharmaceutical combinations
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX388592B (es) Compuestos y metodos terapeuticos.
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
TN2019000032A1 (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
AR099416A1 (es) Terapia combinada para la hipertensión resistente
MX2018001684A (es) Metodo de curacion de heridas.
MX2017003140A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
AR103636A1 (es) Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol